BlackRock Advisors’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$12.5M Buy
106,414
+1,985
+2% +$227K 0.01% 777
2016
Q3
$11.8M Buy
104,429
+147
+0.1% +$15.5K 0.01% 787
2016
Q2
$9.68M Buy
104,282
+10,519
+11% +$903K 0.01% 837
2016
Q1
$7.34M Sell
93,763
-79,794
-46% -$5.75M 0.01% 935
2015
Q4
$12.7M Buy
173,557
+37,536
+28% +$2.68M 0.01% 713
2015
Q3
$10.1M Buy
136,021
+36,459
+37% +$2.61M 0.01% 781
2015
Q2
$6.39M Buy
99,562
+85,566
+611% +$5.92M 0.01% 913
2015
Q1
$1.08M Hold
13,996
﹤0.01% 1514
2014
Q4
$1.04M Sell
13,996
-828
-6% -$58.1K ﹤0.01% 1472
2014
Q3
$873K Sell
14,824
-768
-5% -$48.6K ﹤0.01% 1522
2014
Q2
$1.04M Hold
15,592
﹤0.01% 1469
2014
Q1
$946K Buy
15,592
+440
+3% +$26.2K ﹤0.01% 1578
2013
Q4
$806K Buy
15,152
+810
+6% +$42.6K ﹤0.01% 1661
2013
Q3
$715K Sell
14,342
-594
-4% -$28.5K ﹤0.01% 1648
2013
Q2
$670K Buy
+14,936
New +$653K ﹤0.01% 1614

Other funds holding IDXX

BlackRock Advisors's IDXX Position: Q4 2016 in Review

BlackRock Advisors increased its Idexx Laboratories (IDXX) stake by 1.9% in Q4 2016, buying an estimated $227K and bringing the position to 106,414 shares worth $12.5M. The position accounts for 0.01% of the portfolio, ranked #777.

BlackRock Advisors first reported a position in IDXX in Q2 2013 and has held it in 15 quarters since. The position peaked at $12.7M in Q4 2015. 522 funds tracked by Wall St. Rank hold IDXX as of Q4 2016.

  • BlackRock Advisors held 106,414 shares of Idexx Laboratories worth $12.5M as of Q4 2016.
  • BlackRock Advisors bought 1,985 Idexx Laboratories shares in Q4 2016, an estimated $227K.
  • Idexx Laboratories made up 0.01% of BlackRock Advisors's portfolio in Q4 2016, its #777 holding.
  • BlackRock Advisors first reported a position in Idexx Laboratories in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Idexx Laboratories position peaked at $12.7M in Q4 2015.
  • 522 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.